A Phase 2 interventional study of SPI-62 and Placebo in Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion and Cortisol Excess, sponsored by Sparrow Pharmaceuticals. Completed at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Sparrow Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Cushing Syndrome with a site in United States — 14 open to participants now, 17 under way, none of them phase 3. Cushing Syndrome · United States.
Among the 58 studies in Cushing Syndrome with a site in United States, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2022, is one of 17 in phase 2, and was the 43rd registered.
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
Browse Cushing Syndrome studies →14 of the 58 studies in Cushing Syndrome with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
RECORDATI GROUP · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Sparrow Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 8 · Phase 4 3
First in 1982; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 44 across 58 interventional studies indexed under Cushing Syndrome.
Median enrollment 35 across the 34 interventional studies, 206 across the 23 observational. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 58 have an industry lead sponsor. The 10 most frequent:
Sparrow Pharmaceuticals is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Sparrow Pharmaceuticals has 2 studies filed under Cushing Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Cushing Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03364803Memorial Sloan Kettering Cancer CenterCollecting Information About Treatment Results for Patients With Cushing's Syndrome | 2026-11-28 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07104812Mayo ClinicImpact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) | 2027-01 |
| NCT05382156RECORDATI GROUPNon-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome | 2027-06 |
| NCT03708900RECORDATI GROUPPharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | 2027-07-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 58 studies in Cushing Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.
This is a multicenter, randomized, placebo-controlled, Phase 2 study to evaluate the pharmacologic effect, efficacy, and safety of SPI-62 in subjects with ACTH-dependent Cushing's syndrome. Each subject who provides consent and meets all inclusion and exclusion criteria will participate in a screening period (Days -35 to -8), a baseline period (Days -7 to -1), and a treatment period (Day 1 of Week 1 to Day 168 ± 3 days of Week 24) and, the option of long-term extension. Subjects have the option to continue with the study on active study drug and return to the site every 3 months for blood tests and study drug dispensing. The visits may be conducted remotely if testing can be arranged.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active drug by mouth each morning for up to 12 weeks
Drug: SPI-62 · Drug: Placebo
Placebo by mouth each morning for up to 12 weeks
Drug: SPI-62 · Drug: Placebo
11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
Inactive tablets identical to SPI-62 tablets
Change from baseline in urinary HSD-1 ratio
The urinary HSD-1 ratio (tetrahydrocortisol + allotetrahydrocortisol ) / tetrahydrocortisone will be used as a biomarker of HSD-1 activity in liver. The primary analysis will include only subjects with Cushing's disease.
Time frame: Baseline to 6 weeks
Treatment emergent adverse events
Adverse events including clinically significant abnormal values on clinical laboratory evaluations, continuous glucose monitoring (CGM), 12-lead ECGs, vital signs measurements (including orthostatic vital sign measurements), physical examinations, and HPA and HPG axis biomarkers
Time frame: Baseline through 24 weeks of treatment
Ran from Sep 2022 to primary completion in Aug 2025, 35 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ASP3662
Sparrow Pharmaceuticals